Enveric Biosciences Inc., a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, has announced the filing of a new provisional patent application. This application pertains to a newly identified group of molecules with potential to address neurodegenerative diseases. According to Enveric, these molecules might offer therapeutic candidates for conditions such as Alzheimer's Disease by promoting BDNF signaling, a known therapeutic target in neurodegenerative diseases. A prototype molecule from this family has demonstrated promising pharmacokinetic characteristics in preliminary in vivo testing. Further investigation is planned to explore the therapeutic potential of these molecules.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.